www.clusterconsortium.org.uk
@cluster_tweet

WHERE DOES OUR DATA COME FROM?

JIA-UVEITIS CLINICAL TRIALS

Representing ~150 case of JIA-Uveitis

SYCAMORE: Clinical trial to establish the clinical effectiveness, safety and cost effectiveness of Adalimumab for the treatment of JIA-Uveitis


APTITUDE: Clinical trial to establish the efficacy of Tocilizumab for treating JIA-Uveitis in children who have not improved with Methotrexate or anti-TNF treatments

JIA OBSERVATIONAL COHORT STUDIES

Representing ~5000 cases of JIA, with clinical data, biological samples, and significant 'omics' data

Childhood Arthritis Response to Medication Study

CHARMS: Immunological and genetic mechanisms of response to standard disease treatment in JIA



JIAP: to improve understanding of what causes JIA and through this knowledge to improve the clinical management of JIA



CAPS: Assesses long term patient outcomes in JIA from initial diagnosis. Includes psychology (particularly pain), pre and post treatment core outcome variables, clinical and genetic factors.

BSPAR ETANERCEPT COHORT STUDY

BSPAR: Drug effectiveness and safety study investigating Etanercept and its biosimilars in children with JIA

BCRD: Drug effectiveness and safety study investigating biologic treatments (excluding Etanercept and its biosimilars) in children with JIA

CLUSTER follows **FAIR** (**F**indable, **A**ccessible, **I**nteroperable, **R**eproducible) principles for data sharing, data and sample access. Find out more about FAIR principles here